WASHINGTON — The Trump administration is nearing deals with Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs and expand access to them, people familiar with the talks told STAT.
The companies have been close to a deal for weeks, one lobbyist with knowledge of the negotiations said, echoing others who said they believe the parties are closing in on an agreement. The deals have not yet been announced, and the details could still change.
The agreement is expected to include Medicare coverage of the drugs for weight loss, the people said. Medicare has covered the injections to treat diabetes and some other conditions, but not to help people lose weight. The companies would also agree to sell the drugs directly to consumers for less than their list prices, several news outlets reported.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.